Pompeu Fabra University

Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries

Retrieved on: 
Wednesday, January 17, 2024

FREMONT, Calif. and BARCELONA, Spain, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, has signed an agreement with the Centre for Genomic Regulation (CRG) and the Pompeu Fabra University (UPF) to drive technological innovation and accelerate discoveries for the scientific community.

Key Points: 
  • FREMONT, Calif. and BARCELONA, Spain, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, has signed an agreement with the Centre for Genomic Regulation (CRG) and the Pompeu Fabra University (UPF) to drive technological innovation and accelerate discoveries for the scientific community.
  • Cytek’s collaboration serves as a testament to the substantial impact of its technology, laying the groundwork for expansion into new applications.
  • Under the terms of the agreement, Cytek will provide new, state-of-the-art spectral cytometry platforms – along with trained support personnel – to the CRG-UPF Flow Cytometry Unit’s headquarters.
  • The Unit, founded in 2001 and based in the Barcelona Biomedical Research Park, is a worldwide reference site for advanced flow cytometry applications.

Launch of Scopus AI to Help Researchers Navigate the World of Research

Retrieved on: 
Tuesday, January 16, 2024

Developed and tested with the research community, Scopus AI combines the world's largest database of curated scientific literature with responsible AI.

Key Points: 
  • Scopus AI is based on Scopus' trusted content from over 27,000 academic journals, from more than 7,000 publishers worldwide, with over 1.8 billion citations, and includes over 17 million author profiles.
  • Scopus content is vetted by an independent board of world-renowned scientists and librarians who represent the major scientific disciplines.
  • Since the alpha launch in August 2023, thousands of researchers across the world have tested Scopus AI.
  • Their feedback has reinforced that, as generative AI evolves, researchers want trustworthy, cited research that is relevant and highly personalized to their needs.

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

Retrieved on: 
Wednesday, November 29, 2023

Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.

Key Points: 
  • Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.
  • As part of the next growth phase of the company, Paolo Michieli, PhD, (Founder and formerly Chief Scientific Officer) and Torsten Dreier, PhD, (previously Chief Development Officer) will continue at Agomab as senior advisors and members of the Scientific Advisory Board (SAB).
  • “Angelika’s extensive experience and deep knowledge as a senior drug developer will be of great value to the Board and our company.
  • Andrea Sáez was COO/CSO at Origo Biopharma where she led the development of ALK5 inhibitor programs through preclinical and early clinical stages.

ZGF Team Wins Global Laboratory Design Competition for Research Center at Historic Barcelona Site

Retrieved on: 
Wednesday, January 11, 2023

BARCELONA, Spain, Jan. 11, 2023 /PRNewswire/ -- A jury has selected ZGF Architects with its Barcelona-based teammates MIRAG/Double Twist as the architectural competition winner for the design of a net-positive research center whose visionary transdisciplinary research is anticipated to foster new fields of knowledge and approaches to planetary well-being. The new laboratory, the Mercat del Peix Research Center, will unite global experts in the experimental sciences, social sciences, and humanities to address the world's most complex and vexing challenges related to the future of our planet, including biodiversity loss and climate change economics and governance.

Key Points: 
  • "Together with our partners at MIRAG/Double Twist, ZGF brings our expertise in sustainable laboratory design to create a net-positive home for the world's most impactful planetary-health research," said Ted Hyman, Managing Partner of ZGF.
  • "As a competition team, our expertise combines an understanding of the culturally important site and the complexities of building sustainable laboratories.
  • The caliber of research and knowledge transfer anticipated for this world-class hub drew a remarkable number of participants to the design competition.
  • In this manner, the research center interprets and extends the province of the park, and the nature of the park flourishes within the building.

PPG appoints Pedro Serret Salvat as president and general counsel, EMEA

Retrieved on: 
Monday, January 9, 2023

PPG (NYSE:PPG) today announced that Pedro Serret Salvat, general counsel, PPG EMEA (Europe, Middle East and Africa), will become president and general counsel, PPG EMEA, effective immediately.

Key Points: 
  • PPG (NYSE:PPG) today announced that Pedro Serret Salvat, general counsel, PPG EMEA (Europe, Middle East and Africa), will become president and general counsel, PPG EMEA, effective immediately.
  • Serret Salvat will continue to report to PPG senior vice president and general counsel, Anne Foulkes.
  • View the full release here: https://www.businesswire.com/news/home/20230106005443/en/
    Pedro Serret Salvat, general counsel, PPG EMEA (Europe, Middle East and Africa), was appointed president and general counsel, PPG EMEA.
  • “Pedro will drive a One PPG approach across our operations in EMEA to maximize profitable growth through alignment and synergies across the region.”
    Serret Salvat joined PPG in 2011 as the regional head of legal affairs and was appointed as general counsel, EMEA in 2016.

Enfinity Global appoints Julio Fournier Chief Growth Officer

Retrieved on: 
Monday, December 12, 2022

MIAMI, Dec. 12, 2022 /PRNewswire/ -- Enfinity Global, a leader in renewable energy, has announced the appointment of Julio Fournier Fisas as Chief Growth Officer to accelerate the company's execution across various strategies, including storage and the commercialization of energy.

Key Points: 
  • MIAMI, Dec. 12, 2022 /PRNewswire/ -- Enfinity Global, a leader in renewable energy, has announced the appointment of Julio Fournier Fisas as Chief Growth Officer to accelerate the company's execution across various strategies, including storage and the commercialization of energy.
  • Before joining Enfinity Global, Julio served as Global Vice President and General Manager for EMEA at Canadian Solar.
  • "I am thrilled to join Enfinity Global and the team as the company is taking the next step in its growth strategy.
  • As a global renewable energy solutions platform, Enfinity Global focuses on developing, financing, building, operating, and owning renewable energy assets.

Enfinity Global appoints Julio Fournier Chief Growth Officer

Retrieved on: 
Monday, December 12, 2022

MIAMI, Dec. 12, 2022 /PRNewswire/ -- Enfinity Global, a leader in renewable energy, has announced the appointment of Julio Fournier Fisas as Chief Growth Officer to accelerate the company's execution across various strategies, including storage and the commercialization of energy.

Key Points: 
  • MIAMI, Dec. 12, 2022 /PRNewswire/ -- Enfinity Global, a leader in renewable energy, has announced the appointment of Julio Fournier Fisas as Chief Growth Officer to accelerate the company's execution across various strategies, including storage and the commercialization of energy.
  • Before joining Enfinity Global, Julio served as Global Vice President and General Manager for EMEA at Canadian Solar.
  • "I am thrilled to join Enfinity Global and the team as the company is taking the next step in its growth strategy.
  • As a global renewable energy solutions platform, Enfinity Global focuses on developing, financing, building, operating, and owning renewable energy assets.

Mentice AB intends to acquire all assets related to the software solution Ankyras from the Spanish corporation Galgo Medical S.L.

Retrieved on: 
Thursday, June 9, 2022

The Acquisition is characterized as a technology acquisition as this solution is in an early phase of its commercialization.

Key Points: 
  • The Acquisition is characterized as a technology acquisition as this solution is in an early phase of its commercialization.
  • However, the solution has been developed for a long time by Galgo and the software Ankyras is patent protected and CE-marked product (Medical Device Regulation MDR) with technology published by Galgo since 2013.
  • Ankyras is an advanced cloud-based analysis solution that allows a physician to plan treatment for a specific patient.
  • This disclosure contains information that Mentice AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).

Mentice AB intends to acquire all assets related to the software solution Ankyras from the Spanish corporation Galgo Medical S.L.

Retrieved on: 
Thursday, June 9, 2022

The Acquisition is characterized as a technology acquisition as this solution is in an early phase of its commercialization.

Key Points: 
  • The Acquisition is characterized as a technology acquisition as this solution is in an early phase of its commercialization.
  • However, the solution has been developed for a long time by Galgo and the software Ankyras is patent protected and CE-marked product (Medical Device Regulation MDR) with technology published by Galgo since 2013.
  • Ankyras is an advanced cloud-based analysis solution that allows a physician to plan treatment for a specific patient.
  • This disclosure contains information that Mentice AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).